Susan Moran, M.D., M.S.C.E.
Susan Moran, M.D., M.S.C.E., is chief medical officer of QED Therapeutics. Dr. Moran has over 20 years of industry and academic experience, successfully leading Phase 1 to Phase 3 clinical trials and NDA submissions. Before joining QED, she was Vice President and Head of Clinical Development for Puma Biotechnology and previously held senior roles at Millennium Pharmaceuticals and Genzyme. She has participated in the development, registration, and post-marketing support of products for breast cancer, prostate cancer, thyroid cancer, multiple sclerosis, and other disorders.
Dr. Moran is a board-certified internist who was previously on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. She received her B.A. degree from the University of Virginia, M.D. degree from Duke University, and Master’s of Science in Clinical Epidemiology from the University of Pennsylvania School of Medicine. She completed a residency and fellowship in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in cancer prevention at the Harvard School of Public Health.